Skip to main content
Top
Published in: Annals of Hematology 3/2020

01-03-2020 | Thymoma | Original Article

Immunosuppressive therapy for elderly-acquired pure red cell aplasia: cyclosporine A may be more effective

Authors: Xiaoqing Liu, Xingyu Lu, Lang Chen, Yan Yang, Xuemei Wu, Ruinan Lu, Shuai Wang, Jianfu Zhang, Ming Hong, Yu Zhu, Guangsheng He, Jianyong Li

Published in: Annals of Hematology | Issue 3/2020

Login to get access

Abstract

This current study retrospectively analyzed the clinical characteristics of 69 adult patients with acquired pure red cell aplasia (PRCA) including 40 elderly and 29 non-elderly patients from September 2009 to June 2019. The remission induction therapy regimens included cyclosporine A (CsA), corticosteroids (CS), or other immunosuppressive agents. The overall response rate was 55% (22/40) in the elderly group compared with 75.9% (22/29) in non-elderly patients (P = 0.075). In elderly patients, the best remission was achieved in the group treated with CsA than those treated with CS or other immunosuppressive agents (83.3% vs 26.7% vs 42.9%%, P = 0.004). However, outcomes of remission were similar among different treatment groups (P = 0.458) in non-elderly patients. CS induced a higher response rate in the non-elderly than that in the elderly (88.9% vs 26.7%, P = 0.009). By univariate and multivariate analysis, the clinical efficacy of elderly patients with acquired PRCA was closely associated with an induction regimen of CsA (P = 0.009; P = 0.017). In conclusion, CsA might produce higher response rate than CS and other drugs in elderly patients with acquired PRCA.
Literature
1.
go back to reference Sawada K, Fujishima N, Hirokawa M (2008) Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 142(4):505–514CrossRef Sawada K, Fujishima N, Hirokawa M (2008) Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 142(4):505–514CrossRef
2.
3.
go back to reference Means RT Jr, Dessypris EN, Krantz SB (1991) Treatment of refractory pure red cell aplasia with cyclosporine A: disappearance of IgG inhibitor associated with clinical response. Br J Haematol 78(1):114–119CrossRef Means RT Jr, Dessypris EN, Krantz SB (1991) Treatment of refractory pure red cell aplasia with cyclosporine A: disappearance of IgG inhibitor associated with clinical response. Br J Haematol 78(1):114–119CrossRef
4.
go back to reference Dessypris EN (1988) Pure red cell aplasia. Johns Hopkins University Press, Baltimore Dessypris EN (1988) Pure red cell aplasia. Johns Hopkins University Press, Baltimore
5.
go back to reference Dessypris EN, Lipton JM (2004) Red cell aplasia. In: Wintrobe’s clinical hematology, 11th edn. Lippincott Williams &Wilkins, Philadelphia, pp 1421–1427 Dessypris EN, Lipton JM (2004) Red cell aplasia. In: Wintrobe’s clinical hematology, 11th edn. Lippincott Williams &Wilkins, Philadelphia, pp 1421–1427
6.
go back to reference Sawada K, Hirokawa M, Fujishima N (2009) Diagnosis and management of acquired pure red cell aplasia. Hematol Oncol Clin North Am 23(2):249–259CrossRef Sawada K, Hirokawa M, Fujishima N (2009) Diagnosis and management of acquired pure red cell aplasia. Hematol Oncol Clin North Am 23(2):249–259CrossRef
7.
go back to reference Wu X, Wang S, Lu X, Shen W, Qiao C, Wu Y, Lu R, Wang S, Zhang J, Hong M, Zhu Y, Li J, He G (2018) Response to cyclosporine A and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center. Int J Hematol 108(2):123–129CrossRef Wu X, Wang S, Lu X, Shen W, Qiao C, Wu Y, Lu R, Wang S, Zhang J, Hong M, Zhu Y, Li J, He G (2018) Response to cyclosporine A and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center. Int J Hematol 108(2):123–129CrossRef
8.
go back to reference Balasubramanian SK, Sadaps M, Thota S, Aly M, Przychodzen BP, Hirsch CM, Visconte V, Radivoyevitch T, Maciejewski JP (2018) Rational management approach to pure red cell aplasia. Haematologica 103(2):221–230CrossRef Balasubramanian SK, Sadaps M, Thota S, Aly M, Przychodzen BP, Hirsch CM, Visconte V, Radivoyevitch T, Maciejewski JP (2018) Rational management approach to pure red cell aplasia. Haematologica 103(2):221–230CrossRef
9.
go back to reference Mamiya S, Itoh T, Miura AB (1997) Acquired pure red cell aplasia in Japan. Eur J Haematol 59(4):199–205CrossRef Mamiya S, Itoh T, Miura AB (1997) Acquired pure red cell aplasia in Japan. Eur J Haematol 59(4):199–205CrossRef
10.
go back to reference Hirokawa M, Sawada K, Fujishima N, Nakao S, Urabe A, Dan K, Fujisawa S, Yonemura Y, Kawano F, Omine M, Ozawa K, PRCA Collaborative Study Group (2008) Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica 93(1):27–33CrossRef Hirokawa M, Sawada K, Fujishima N, Nakao S, Urabe A, Dan K, Fujisawa S, Yonemura Y, Kawano F, Omine M, Ozawa K, PRCA Collaborative Study Group (2008) Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica 93(1):27–33CrossRef
11.
go back to reference Kwong YL, Wong KF, Liang RH, Chu YC, Chan LC, Chan TK (1996) Pure red cell aplasia: clinical features and treatment results in 16 cases. Ann Hematol 72(3):137–140CrossRef Kwong YL, Wong KF, Liang RH, Chu YC, Chan LC, Chan TK (1996) Pure red cell aplasia: clinical features and treatment results in 16 cases. Ann Hematol 72(3):137–140CrossRef
12.
go back to reference Sawada K, Hirokawa M, Fujishima N, TeramuraM BM, Dan K, Tsurumi H, Nakao S, Urabe A, Omine M, Ozawa K, PRCA Collaborative Study Group (2007) Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica 92(8):1021–1028CrossRef Sawada K, Hirokawa M, Fujishima N, TeramuraM BM, Dan K, Tsurumi H, Nakao S, Urabe A, Omine M, Ozawa K, PRCA Collaborative Study Group (2007) Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica 92(8):1021–1028CrossRef
13.
go back to reference Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, Teramura M, Karasawa M, Arai A, Yonemura Y, Nakao S, Urabe A, Omine M, Ozawa K, PRCA Collaborative Study Group (2008) Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 93(10): 1555–1559CrossRef Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, Teramura M, Karasawa M, Arai A, Yonemura Y, Nakao S, Urabe A, Omine M, Ozawa K, PRCA Collaborative Study Group (2008) Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 93(10): 1555–1559CrossRef
14.
go back to reference Clark DA, Dessypris EN, Krantz SB (1984) Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients. Blood 63(2):277–286CrossRef Clark DA, Dessypris EN, Krantz SB (1984) Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients. Blood 63(2):277–286CrossRef
Metadata
Title
Immunosuppressive therapy for elderly-acquired pure red cell aplasia: cyclosporine A may be more effective
Authors
Xiaoqing Liu
Xingyu Lu
Lang Chen
Yan Yang
Xuemei Wu
Ruinan Lu
Shuai Wang
Jianfu Zhang
Ming Hong
Yu Zhu
Guangsheng He
Jianyong Li
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Keywords
Thymoma
Thymoma
Published in
Annals of Hematology / Issue 3/2020
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-020-03926-6

Other articles of this Issue 3/2020

Annals of Hematology 3/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.